Aflibercept (Eylea®) Injection

Covers Eylea (aflibercept) for FDA‑approved indications (neovascular/wet AMD, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy) and specified off‑label compendial neovascular ophthalmic uses; indications not listed are excluded. Approval requires diagnosis of a listed indication, administration by or under the supervision of an ophthalmologist, is granted for 12 months, and follows dosing of 2 mg intravitreal — AMD: every 4 weeks ×3 then every 8 weeks; RVO: every 4 weeks; DME/DR: every 4 weeks for the first 5 injections then every 8 weeks.

"Neovascular (wet) age-related macular degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.